In a recent transaction, Mikhail Eydelman, Senior Vice President, General Counsel, and Corporate Secretary of Vaxcyte, Inc. (NASDAQ:PCVX), sold a significant amount of the company's stock. Eydelman offloaded shares worth over $628,000, according to a Form 4 filing with the Securities and Exchange Commission.
The executive sold 1,414 shares at an average price of $113.381, with the price ranging from $112.795 to $113.73. Additionally, 3,056 shares were sold at an average price of $114.369, within a price range of $113.83 to $114.82. The final batch of 1,030 shares was sold at an average price of $115.012, with individual shares fetching between $114.95 to $115.16. The transactions were conducted under a Rule 10b5-1 trading plan, which Eydelman had adopted on June 11, 2024.
On the same day, Eydelman also exercised options to acquire 5,500 shares of Vaxcyte common stock at a price of $21.41 per share, totaling $117,755. This transaction was part of a pre-determined vesting schedule, as outlined in a footnote to the filing. Following these transactions, Eydelman's direct ownership in Vaxcyte stands at 28,623 shares of common stock.
Vaxcyte, Inc., headquartered in San Carlos, California, operates in the biotechnology sector, focusing on the development of vaccines. The company, formerly known as SutroVax Inc., is incorporated in Delaware and has been publicly traded since changing its name in 2015.
Investors often monitor insider trading activity to gain insights into a company's financial health and executive confidence. Transactions by high-level executives can be particularly noteworthy, as they may reflect the insiders' view of the company's current valuation and future prospects.
In other recent news, Vaxcyte, a clinical-stage biotech firm, announced positive top-line results from the Phase 1/2 trial of its vaccine candidate, VAX-31. This development prompted Mizuho to increase its price target for Vaxcyte shares to $163 from $113, maintaining an Outperform rating. Other firms like BofA Securities, BTIG, and Jefferies also increased their price targets following these promising results.
Recent developments also include a successful public offering by Vaxcyte that raised approximately $1.5 billion, reflecting investor confidence in the company's mission to develop vaccines against bacterial infections. Additionally, Vaxcyte appointed John P. Furey to its Board of Directors, indicating changes in the company's corporate structure.
Vaxcyte's promising vaccine pipeline includes candidates such as VAX-31 and VAX-24, aimed at preventing invasive pneumococcal disease. The company plans to progress VAX-31 into Phase 3 trials for adult indication by mid-2025. These recent developments reflect Vaxcyte's ongoing progress in the vaccine industry.
InvestingPro Insights
To complement the recent insider trading activity at Vaxcyte, Inc. (NASDAQ:PCVX), InvestingPro data provides additional context for investors. The company's market capitalization stands at $13.76 billion, reflecting significant investor interest in its vaccine development pipeline.
Vaxcyte's stock has shown remarkable performance, with a 140.78% price total return over the past year and a 75.5% return in the last six months. This aligns with an InvestingPro Tip highlighting the company's "Strong return over the last three months," which may explain the timing of the insider's decision to sell shares.
Despite the positive stock performance, it's important to note that Vaxcyte is not currently profitable. An InvestingPro Tip indicates that "Analysts do not anticipate the company will be profitable this year," which is consistent with the reported operating income of -$577.16 million for the last twelve months as of Q2 2024.
Interestingly, another InvestingPro Tip reveals that Vaxcyte "Holds more cash than debt on its balance sheet," suggesting a solid financial position that could support ongoing research and development efforts. This financial stability may contribute to investor confidence despite the current lack of profitability.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Vaxcyte, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.